The Ethereum Foundation has launched an open technical challenge to prove a finite worst-case step bound for verifying Ethereum blocks on a 64-bit RISC-V model. Currently, the best known bound is infinite, meaning no fixed upper limit has been certified. This challenge aims to establish a certified upper bound on computation steps, which is crucial for predictable costs and security in zero-knowledge proofs used in Ethereum's zkVMs. A proven limit helps prevent denial-of-service attacks by ensuring provers can handle the most complex blocks within a known budget. The challenge is open-ended with no prizes or deadlines, inviting contributors to improve on the baseline infinite score.
The Ethereum Foundation's evm.fast challenge to verify block limits provides context for cryptocurrency market activity. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Nov 03, 2026 11:21 WIB: out of 50 major cryptocurrencies, only 5 rose while 44 fell. Among notable movers, ZIL dropped 5.81% to Rp32 with a typical hold time of 134 days and a 63% sell order activity, contrasting with SAND which fell 5.11% to Rp795 but had a balanced order activity of 48% sell and 52% buy.
ZYT officially introduced its Prax Drive System™, a commercial vehicle technology, partnering with leading Chinese truck makers like XCMG, Shacman, and Sinotruk. The system supports heavy trucks, buses, light trucks, and vans, with production underwa...
Yaoyao, the Asia-Pacific growth lead for the Solana Foundation, has announced her departure after three and a half years with the organization. She joined in 2023 and played a key role in expanding Solana's presence in Greater China, including foundi...
On November 2, spot Bitcoin exchange-traded funds (ETFs) experienced net outflows totaling $399 million, primarily driven by Blackrock's IBIT fund which alone lost $405 million. Despite this, Fidelity's FBTC fund recorded the largest inflow of $6.68 ...
The Rose Income Garden portfolio highlights VICI Properties and W. P. Carey as the most undervalued dividend raisers for October, with VICI offering a 7.52% yield and expanding beyond Las Vegas. The portfolio, which includes 69 investments across all...
ARS Pharmaceuticals is rated Buy as its current stock price undervalues its pipeline potential despite commercial challenges. Its main product, neffy, an intranasal epinephrine spray, faces slow market adoption and insurance issues but holds promise ...
